Dyax Corp. Announces Intent to Close Belgium Research Facility
Advertisement
Dyax Corp. announced that the Board of Directors of its Belgian subsidiary, Dyax SA, has initiated discussions with its 24 employees as it considers a possible closure of the Liege-based research facility. The closure option would allow for reduction in operating expenses and corresponds with Dyax's strategic plan to direct its resources toward the commercialization of DX-88 in hereditary angioedema. Additionally, the closure option would help optimize Dyax's research and development capabilities by consolidating its discovery and preclinical programs at its headquarters in Cambridge, MA. In accordance with Belgian law, no final decision is expected until some time in June 2008.
Expenses related to the Belgium research facility have risen steadily as a result of the depreciating U.S. dollar, negatively effecting operating costs. If completed, Dyax expects the closure would contribute approximately $7.0 million in annual savings after 2008 and result in a charge of approximately $5.3 million in the remaining quarters of 2008.
"This strategic decision is difficult but necessary for the ongoing growth objectives of Dyax. We are in a crucial period of our late-stage DX-88 clinical program, which requires substantial resources and dedication. The consolidation of our research facilities would contribute to the strategy of reducing our operating costs and increasing our productivity and efficiency," commented Henry E. Blair, Chairman, President and Chief Executive Officer. "The contributions made by the Liege research team are deeply appreciated."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Your brain digitally remastered for clarity of thought - Neurofeedback can enhance the signal-to-noise ratio in thought, enabling a sharper focus on tasks
Nelson M. Sims joins Aastrom Biosciences' Board of Directors
Oncolytics Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development
EKF Diagnostics acquires Selah Genomics and DiaSpect Medical AB
Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect
Kiel Möbius Prize goes to renowned American microbiome researcher
Innovative Roche cancer medicine Avastin approved in EU - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer
